Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 4/20 | 0.55 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.55 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.55 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.55 |
| ▸ | VCP | P55072 | 14/20 | 0.54 |
| ▸ | HTR6 | P50406 | 1/20 | 0.49 |
| ▸ | PDE5A | O76074 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1623648 | 0.79 | HTR2C (0.57) | VCPHTR6 | |
| SCHEMBL3641766 | 0.73 | PDE5A (0.73) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| SCHEMBL3642572 | 0.73 | PDE5A (0.81) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| SCHEMBL1621297 | 0.72 | CETP (0.48) | VCP | |
| SCHEMBL15558834 | 0.71 | VCP (0.73) | VCP | |
| SCHEMBL18095880 | 0.71 | VCP (0.66) | VCP | |
| SCHEMBL291798 | 0.71 | PDE4A (0.96) | PDE4APDE4BPDE4CPDE4DHTR6 | |
| SCHEMBL15549232 | 0.71 | VCP (0.79) | VCP | |
| SCHEMBL3643346 | 0.71 | PDE5A (0.79) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| SCHEMBL15421073 | 0.70 | VCP (1.00) | VCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7928099-B2 | Pyrimido [4,5-D] azepine derivatives as 5-HT2c agonists | PFIZER INC (US) | 2011-04-19 | — | — | US | disclosed |
| US-7928099-B2 | Pyrimido [4,5-D] azepine derivatives as 5-HT2c agonists | PFIZER INC (US) | 2011-04-19 | — | — | US | disclosed |
| US-7928099-B2 | Pyrimido [4,5-D] azepine derivatives as 5-HT2c agonists | PFIZER INC (US) | 2011-04-19 | — | — | US | disclosed |
| US-20100113422-A1 | Pyrimido [4,5-D] Azepine Derivatives As 5-HT2C Agonists | ANDREWS MARK | 2010-05-06 | — | — | US | disclosed |
| US-20100113422-A1 | Pyrimido [4,5-D] Azepine Derivatives As 5-HT2C Agonists | ANDREWS MARK | 2010-05-06 | — | — | US | disclosed |
| US-20100113422-A1 | Pyrimido [4,5-D] Azepine Derivatives As 5-HT2C Agonists | ANDREWS MARK | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113422-A1 | Pyrimido [4,5-D] Azepine Derivatives As 5-HT2C Agonists | HTR2C, HTR2A, HTR5A | PDE4A 200/4885PDE4B 208/4885PDE4C 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.